JP7077335B2 - プロテインキナーゼ阻害剤 - Google Patents

プロテインキナーゼ阻害剤 Download PDF

Info

Publication number
JP7077335B2
JP7077335B2 JP2019551918A JP2019551918A JP7077335B2 JP 7077335 B2 JP7077335 B2 JP 7077335B2 JP 2019551918 A JP2019551918 A JP 2019551918A JP 2019551918 A JP2019551918 A JP 2019551918A JP 7077335 B2 JP7077335 B2 JP 7077335B2
Authority
JP
Japan
Prior art keywords
compound
mixture
compounds
alkyl
enantiomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019551918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020503376A5 (enExample
JP2020503376A (ja
Inventor
ホー、カン
Original Assignee
プリンストン ドラッグ ディスカバリー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プリンストン ドラッグ ディスカバリー インコーポレイテッド filed Critical プリンストン ドラッグ ディスカバリー インコーポレイテッド
Publication of JP2020503376A publication Critical patent/JP2020503376A/ja
Publication of JP2020503376A5 publication Critical patent/JP2020503376A5/ja
Application granted granted Critical
Publication of JP7077335B2 publication Critical patent/JP7077335B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019551918A 2016-12-13 2017-12-12 プロテインキナーゼ阻害剤 Active JP7077335B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662433410P 2016-12-13 2016-12-13
US62/433,410 2016-12-13
US201762539785P 2017-08-01 2017-08-01
US62/539,785 2017-08-01
PCT/US2017/065847 WO2018111893A1 (en) 2016-12-13 2017-12-12 Protein kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2020503376A JP2020503376A (ja) 2020-01-30
JP2020503376A5 JP2020503376A5 (enExample) 2020-11-12
JP7077335B2 true JP7077335B2 (ja) 2022-05-30

Family

ID=61829613

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019551918A Active JP7077335B2 (ja) 2016-12-13 2017-12-12 プロテインキナーゼ阻害剤

Country Status (8)

Country Link
US (5) US10479786B2 (enExample)
EP (1) EP3555092A4 (enExample)
JP (1) JP7077335B2 (enExample)
KR (1) KR102582752B1 (enExample)
CN (1) CN108473487B (enExample)
AU (1) AU2017375949B2 (enExample)
CA (1) CA3044066A1 (enExample)
WO (1) WO2018111893A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10479786B2 (en) 2016-12-13 2019-11-19 Princeton Drug Discovery, Inc Protein kinase inhibitors
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
WO2020123277A1 (en) * 2018-12-10 2020-06-18 Princeton Drug Discovery Inc. Protein kinase inhibitor prodrugs
KR102256804B1 (ko) * 2019-02-26 2021-05-26 한국화학연구원 N-페닐-2-(피리미딘-4-일아미노)티아졸-5-카복사미드 유도체, 이의 약학적으로 허용 가능한 염 및 이를 유효성분으로 함유하는 미백 소재 조성물
AU2021230289A1 (en) 2020-03-03 2022-09-29 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
CA3229560A1 (en) 2021-08-25 2023-03-02 Christopher L. Vandeusen Eif4e inhibitors and uses thereof
JP2024532276A (ja) 2021-08-25 2024-09-05 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503866A (ja) 2002-10-02 2006-02-02 ブリストル−マイヤーズ　スクイブ　カンパニー 癌を処置するための相乗的な方法および組成物
WO2006099474A1 (en) 2005-03-15 2006-09-21 Bristol-Myers Squibb Company 'n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites
JP2006523216A (ja) 2003-03-24 2006-10-12 ブリストル−マイヤーズ　スクイブ　カンパニー 環状プロテインチロシンキナーゼインヒビター
WO2008150446A1 (en) 2007-05-30 2008-12-11 Congxin Liang Inhibitors of protein kinases
US20090076025A1 (en) 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched dasatinib
JP2010502742A (ja) 2006-09-11 2010-01-28 キュリス，インコーポレイテッド 亜鉛結合部分を含むチロシンキナーゼインヒビター
JP2012529511A (ja) 2009-06-08 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー トリアジン誘導体類及びそれらの治療応用
CN104151321A (zh) 2013-05-15 2014-11-19 复旦大学 N-(2-氯-6-甲基苯基)-2[(2-甲基嘧啶-4-基)氨基]噻唑-5-甲酰胺化合物及其制备方法和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2308833A3 (en) 1999-04-15 2011-09-28 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
ES2257461T3 (es) 2000-12-21 2006-08-01 Bristol-Myers Squibb Company Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
US20040209930A1 (en) * 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US20060021105A1 (en) * 2004-07-29 2006-02-02 Wilson Nick L Ergonomic hand protection apparatus
ES2396366T3 (es) 2007-12-10 2013-02-21 Concert Pharmaceuticals Inc. Inhibidores heterocíclicos de quinasas
US8563554B2 (en) 2009-03-17 2013-10-22 Concert Pharmaceuticals, Inc. Deuterated pyrazinoisoquinoline compounds
CA2775155A1 (en) * 2009-10-01 2011-04-07 Csl Limited Method of treatment of philadelphia chromosome positive leukemia
CN101891738B (zh) 2010-02-08 2011-09-28 南京卡文迪许生物工程技术有限公司 达沙替尼多晶型物及其制备方法和药用组合物
NZ717373A (en) 2010-06-03 2017-11-24 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
EP2872159A2 (en) 2012-07-13 2015-05-20 Concert Pharmaceuticals Inc. Deuterated carfilzomib
MX2015012610A (es) 2013-03-14 2016-02-17 Concert Pharmaceuticals Inc Pacritinib deuterizado.
CN104130250B (zh) 2013-05-07 2016-06-22 郑州泰基鸿诺药物科技有限公司 氘代达沙替尼及其制备方法和应用
IL311537A (en) 2014-01-28 2024-05-01 Mayo Found Medical Education & Res Methods and preparations for killing aging cells and for the treatment of diseases and disorders related to aging
US20170224688A1 (en) 2016-02-04 2017-08-10 Acerta Pharma B.V. Methods of Using BTK Inhibitors to Treat Dermatoses
WO2017168454A2 (en) * 2016-04-02 2017-10-05 Sun Pharma Advanced Research Company Limited Novel compounds as btk inhibitors
US10479786B2 (en) * 2016-12-13 2019-11-19 Princeton Drug Discovery, Inc Protein kinase inhibitors

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503866A (ja) 2002-10-02 2006-02-02 ブリストル−マイヤーズ　スクイブ　カンパニー 癌を処置するための相乗的な方法および組成物
JP2006523216A (ja) 2003-03-24 2006-10-12 ブリストル−マイヤーズ　スクイブ　カンパニー 環状プロテインチロシンキナーゼインヒビター
WO2006099474A1 (en) 2005-03-15 2006-09-21 Bristol-Myers Squibb Company 'n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites
JP2010502742A (ja) 2006-09-11 2010-01-28 キュリス，インコーポレイテッド 亜鉛結合部分を含むチロシンキナーゼインヒビター
WO2008150446A1 (en) 2007-05-30 2008-12-11 Congxin Liang Inhibitors of protein kinases
US20090076025A1 (en) 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched dasatinib
JP2012529511A (ja) 2009-06-08 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー トリアジン誘導体類及びそれらの治療応用
CN104151321A (zh) 2013-05-15 2014-11-19 复旦大学 N-(2-氯-6-甲基苯基)-2[(2-甲基嘧啶-4-基)氨基]噻唑-5-甲酰胺化合物及其制备方法和用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Drug Metabolism and Disposition，2009年，Vol. 37, No. 6，pp. 1242-1250

Also Published As

Publication number Publication date
US20180099959A1 (en) 2018-04-12
KR20190091312A (ko) 2019-08-05
AU2017375949B2 (en) 2021-09-09
JP2020503376A (ja) 2020-01-30
KR102582752B1 (ko) 2023-09-22
US10556897B2 (en) 2020-02-11
US20180099961A1 (en) 2018-04-12
CN108473487A (zh) 2018-08-31
AU2017375949A1 (en) 2019-05-23
US10174018B2 (en) 2019-01-08
US20190071437A1 (en) 2019-03-07
US20200123148A1 (en) 2020-04-23
US11236080B2 (en) 2022-02-01
EP3555092A4 (en) 2020-05-13
CA3044066A1 (en) 2018-06-21
WO2018111893A1 (en) 2018-06-21
US10479786B2 (en) 2019-11-19
CN108473487B (zh) 2021-08-03
EP3555092A1 (en) 2019-10-23
US20180099960A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
JP7077335B2 (ja) プロテインキナーゼ阻害剤
US10350210B2 (en) EGFR and ALK dual inhibitor
KR102747104B1 (ko) 단백질 키나아제 저해 활성을 갖는 신규한 피리도[3,4-d]피리미딘-8-온 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
CN103748096B (zh) 作为蛋白激酶抑制剂的吡咯并嘧啶化合物
AU2009329640B2 (en) Preparation method of dihydroindene amide compounds, their pharmaceutical compositions containing compounds thereof and use as protein kinases inhibitor
CN104829610B (zh) 一种新型布鲁顿酪氨酸激酶抑制剂
CN105481862B (zh) Flt3激酶的新型抑制剂及其用途
US20150210702A1 (en) Novel pyrrolopyrimidine compounds as inhibitors of protein kinases
US10975082B2 (en) Inhibitor of FLT3 kinase and use thereof
US10266535B2 (en) Inhibitor of FLT3 kinase and use thereof
CN108947974A (zh) 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途
CN107353286A (zh) 新型咪唑并[1,2-b]哒嗪酰胺类Bcr-Abl激酶抑制剂及其制备方法和应用
HK1163054B (en) Preparation method of dihydroindene amide compounds their pharmaceutical compositions containing compounds thereof and use as protein kinases inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200928

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220427

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220513

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220518

R150 Certificate of patent or registration of utility model

Ref document number: 7077335

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250